Triple-positive profile may flag adverse prostate cancer pathology

• by Andrea Surnit

• September 8, 2026

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min

FDA raises TMB threshold for pembrolizumab

Traditional approval narrows eligibility for previously treated solid tumors after efficacy was not confirmed at lower biomarker levels.

• by Mouj Hijazi

• October 23, 2026

• 3 min

FDA expands talazoparib use in prostate cancer

The combination with enzalutamide reduced the risk of radiographic progression or death by 52% .

• by Mouj Hijazi

• October 27, 2026

• 3 min